This large nationwide case-time-control study provides reassurance about the short-term psychiatric safety of GLP-1 RA, showing no specific risk for patients with psychiatric disorders or obesity. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.